Group Management

Jakob Lindberg
Jakob Lindberg
Med Lic, Chief Executive Officer

Jakob Lindberg was appointed as CEO in 2011.

In addition to being CEO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies.

Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.

Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University.

Born: 1972
Holdings in Oncopeptides: 235 409 shares (220,109 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 1,070 employee options* and 204,190 options**.
Other current positions: Director of Affibody Medical AB, Atlas Antibodies AB, Lindberg Life-Science AB and Bostadsrättsföreningen Astraea. Alternate Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.

Birgitta Ståhl
Birgitta Ståhl
MSc, MBA, Chief Financial Officer

Birgitta Ståhl was appointed CFO in 2016.

Previous positions Birgitta has held include COO and acting CFO at Akinion Pharmaceuticals AB and KDev Oncology AB and Vice President Company Operations at Axelar AB, a Swedish drug development company in the field of oncology.

Birgitta holds an MSc Pharm from Uppsala University and an MBA from University of Westminster in London

Born: 1971
Holdings in Oncopeptides: 3,400 shares (Directly owned or affiliated) and 102,595 options**.

Elisabeth Augustsson
Elisabeth Augustsson
MSc, Head of Regulatory Affairs

Elisabeth Augustsson was appointed as Head of Regulatory Affairs in 2015.

In addition to being Head of Regulatory Affairs of Oncopeptides, Elisabeth is the President and Founder of Restracom, which provides consulting services to pharmaceutical companies in the area of regulatory strategies and communication with regulatory authorities.

Elisabeth has previously held roles at a number of life sciences companies including Pharmacia&Upjohn, Medivir AB, Biovitrum AB, Karo Bio AB and Alexion AB.

Elisabeth holds an MSc Pharm from Uppsala University.

Born: 1965
Holdings in Oncopeptides: 72,117 options**.
Other current positions: Chairman of the Board and CEO of Restracom AB.

Paula Boultbee
Paula Boultbee
Chief Commercial Officer

Paula Boultbee was appointed as the Chief Commercial Officer in 2016.

In addition to her role at Oncopeptides, Paula is also a principal at PTB Consulting LLC.

Paula has held a number of roles in life sciences marketing and has experience in the launch and commercialisation of oncology products. Paula has also been responsible for strategic planning and branding. She is currently a director at The Max Foundation, which provides support to people living with cancer. In addition, Paula was previously a director at Isofol AB, a Swedish life sciences business.

Paula is a trained nurse.

Born: 1958
Holdings in Oncopeptides: 102,595 options**.
Other current positions: Chairman of The Max Foundation and adviser to Monocl AB.

Bengt Gustavsson
Bengt Gustavsson
Dr Med Sci, MSc Pharm, Head of Medical Relations

Bengt Gustavsson was appointed Head of Medical Relations 2017.

In addition to his role as Head of Medical Relations at Oncopeptides, Bengt also runs his own consultancy company Sangus Jazz AB.

Previous positions Bengt has held include Nordic Medical Director at Celgene AB and at Novartis Oncology, and Nordic Clinical Research Director at Sanofi-Aventis.
Bengt Gustavsson holds a Master of Science in Pharmacy and is Doctor of Medical Science (Pathology) from Uppsala University. He also holds an EUCOR/ECPM-exam in Pharmaceutical Medicine from the EUCOR-universities in Basel, Freiburg and Strasbourg.

Born: 1962
Holdings in Oncopeptides: 600 shares and 102,595 options**.
Other current positions: Chairman and CEO of Sangus Jazz AB. Board Director of NanexaAB, adviser to Scandinavian CRO AB.

Johan Harmenberg
Johan Harmenberg
MD, PhD, Associate Prof, Chief Medical Officer

Johan Harmenberg was appointed as the Chief Medical Officer in 2012.

Johan has previously held roles at a number of life sciences companies including as CEO for Axelar AB and Akinion AB, Chief Medical Officer at Algeta AB, Vice President Development for Medivir AB and Global Medical Director for Pharmacia Upjohn. He is the author of over 100 publications for a range of scientific journals.

Johan holds a PhD and MD from the Karolinska Institute in Stockholm, Sweden. He is also Associate Professor (Docent) at the same institution.

Born: 1954
Holdings in Oncopeptides: 5,000 shares, 160 employee options* and 72,117 options**.
Other current positions: Chairman of Gungner Medical AB, KarSar Fastigheter AB and Sarak Fastigheter AB.

Fredrik Lehmann
Fredrik Lehmann
PhD, Head of Research and CMC (Chemistry, Manufacturing & Control)

Fredrik Lehmann was appointed Head of CMC in 2010 and Head of Research in 2018.

In addition to being Head of CMC for Oncopeptides, Fredrik is an independent consultant within preclinical research and CMC.

Fredrik has previously held positions at a number of life sciences businesses including Pharmacia, Personal Chemistry, Biovitrum and Recipharm. He has also co-founded six life science companies.

Fredrik holds a PhD in medicinal chemistry from Gothenburg University.

Born: 1976
Holdings in Oncopeptides: 1,000 shares (indirectly owned through OT Lehmann Holding AB), 50 employee options* and 72,117 options**.
Other current positions: Director and CEO of OT Pharmaceuticals AB. Board member of OT Lehmann Holding AB and Chariman of the board of Synartro AB.

Eva Nordström
Eva Nordström
MSc Pharm, Vice President, Head of Clinical Development

Eva Nordström was appointed as Head of Clinical Development in 2012.

Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.

Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.

Born: 1970
Holdings in Oncopeptides: 150,200 shares, 33 employee options* and 102,595 options**.
Other current positions: Alternate Director of Utilica AB.

Rein Piir
Rein Piir
Head of Investor Relations

Rein Piir was appointed as Investor Relations Manager in 2016.

In addition to his role as Investor Relations Manager at Oncopeptides, Rein holds investor relations position at the life sciences company Camurus AB.

Previous roles Rein has held include Head of Strategy at Alecta AB and Head of Analysis at Carnegie Investment Bank AB as well as Chief Financial Officer and Head of Investor Relations at Medivir AB. Rein also worked for several years at the international account anting firm PricewaterhouseCoopers. Rein currently holds directorship at the Swedish life sciences company Integrative Research Laboratories Sweden.

Rein Piir holds a B.Sc. Business Economics and Management from Uppsala University, Sweden.

Born: 1958
Holdings in Oncopeptides: 2,500 shares (Indirectly owned through Piir & Partner AB) and 72,117 options**.
Other current positions: Chairman and CEO of Piir & Partner AB. Board member of Integrative Research Laboratories Sweden AB and L. E. Svensson Snickeri AB.

Christian Jacques
Christian Jacques
MD, MSc, EVP Clinical Strategy and Chief Scientific Officer

Christian Jacques was appointed EVP Clinical Strategy and Chief Scientific Officer in 2018.

In addition to being EVP Clinical Strategy and CSO of Oncopeptides, Christian is Chief Scientific Officer at Pharma Biotech Consultants LLC, which provides consulting services to companies within the area of hemato-oncology.

Christian has previously held roles at a number of life sciences companies including as Vice President Clinical Development at Celgene, where he was in charge of the multiple myeloma clinical development for Celgene products and got approval of pomalidomide (Pomalyst or Imnovid) in the US, EU and several other key countries. He also led the global clinical development for Revlimid. Christian also held roles at Novartis, Johnson & Johnson, Aventis (Formerly Rhone-Poulenc) and Pierre Fabre Oncologie, all within Oncology.

He has more than 54 publications in peer-reviewed journals or at major congresses.

Christian holds an MD degree and Internal Medicine degree from Université Catholique de Louvain, Belgium. Christian has been a hospital practitioner for 10 years.

Born: 1956
Holdings in Oncopeptides: 200,000 options**
Other current positions: Dr Jacques is a member of American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).

* Each employee option entitles the holder to acquire 900 shares per option in the company.
** The options entitles to one share per option in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.

Holdings in Oncopeptides AB as of September 25, 2018.